16 results about "Intimal hyperplasia" patented technology

The invention discloses a modified silk fibroin artificial blood vessel and a preparation method and application thereof.The modified silk fibroin artificial blood vessel comprises a modified silk fibroin composite scaffold and a polyurethane layer, the polyurethane layer is arranged on the modified silk fibroin composite scaffold through electrostatic spinning, and the polyurethane layer is prepared from polyurethane, the modified silk fibroin composite scaffold is prepared from the following raw materials: modified silk fibroin, arginine-glycine-aspartic acid polypeptide modified polycaprolactone, bacterial cellulose, a growth factor and glutaraldehyde. The modified silk fibroin is in bridge connection with the arginine-glycine-aspartic acid polypeptide modified polycaprolactone and is loaded with the growth factor. The comprehensive biocompatibility of the artificial blood vessel can be improved, thrombosis and intimal hyperplasia are effectively inhibited, and therefore the long-term patency rate of the small-caliber artificial blood vessel is greatly increased.

This invention discloses a 3D-printed helical biodegradable anti-inflammatory vascular stent and its preparation method, belonging to the field of vascular stents. The invention uses multiple helical support wires arranged into a tubular shape, with the ends connected in a serpentine transitional manner. The helical support wires are connected by connecting ribs, and the surface is coated. This invention is biodegradable after use, avoiding the harm caused by permanent retention in the body, and has a lower restenosis rate compared to metal stents. The surface of the vascular stent is coated with a spermidine-containing coating to prevent immune rejection of the implanted vascular stent, thereby addressing the problems of inflammation and intimal hyperplasia. The helical structure facilitates contraction and expansion, has good bending flexibility, and the added connecting ribs increase the radial support performance of the vascular stent, better achieving the effect of vascular remodeling. This invention has significant implications in terms of biodegradability, anti-immune rejection, and mechanical properties, and can be used for treatment in different locations such as peripheral and coronary vessels.

The invention discloses a left iliac total vein extravascular stent and an operation method, and belongs to the field of medical instruments. The stent comprises a middle section connecting sleeve frame, an inferior vena cava sleeve frame and a left iliac vein sleeve frame which are integrally formed, the included angle between the three is 135-145 degrees, an elastic silica gel limiting clamping belt is arranged and made of a silicon rubber material, and the crosslinking density and flexibility are regulated and controlled by adjusting the vinyl content. The surgical method comprises the following steps of: minimally invasive laparoscopic approach, implanting a stent after exposing a target blood vessel, and adjusting the position. Direct contact between the built-in stent and the intima is avoided, the intima hyperplasia and thrombus risks are reduced, fatigue resistance and creep resistance are achieved, the stent is attached to the anatomical structure, fixation is stable, minimally invasive recovery is fast, customizable adaptation can be achieved, and the clinical treatment effect and safety are improved.

The invention relates to the technical field of biological medicine and tissue engineering, in particular to a tissue engineering blood vessel and a preparation method and application thereof. The tissue engineering blood vessel is obtained by modifying interleukin 24 (IL-24) on the surface of an acellular blood vessel, after the tissue engineering blood vessel is transplanted into a body, the number of CD31 + and CD34 + cells can be remarkably increased, and infiltration of M2 type macrophages (CD163 +) on the surface of the blood vessel is remarkably increased; the expression of HIF-1 alpha (hypoxia marker) and MMP9 is obviously reduced; the expression of the nerve specific protein S-100 is obviously increased, thrombosis and intimal hyperplasia are effectively inhibited, and the patency rate of transplanted blood vessels is obviously increased.

The application relates to the field of biological medicine, in particular to a medicine for preventing intimal hyperplasia and application thereof, and specifically discloses application of a plasmid in preparation of a medicine for preventing intimal hyperplasia through extra-vascular injection, wherein the plasmid is one or more of HGF plasmid, VEGF plasmid and eNOS plasmid, and the plasmid is a naked plasmid. Through the scheme, a medicine of a safe, simple, efficient and local continuous expression gene delivery mode is developed, the medicine is precisely delivered from outside to inside through an extra-vascular injection path, the problems of easy loss of intraluminal medicine and poor targeting of systemic administration are solved, and the treatment effect of the disease is greatly improved.

The invention relates to an internal arteriovenous fistula stent which comprises a base stent used for covering an arteriovenous anastomotic stoma area and a hybrid stent used for being arranged outside a to-be-anastomosed vein in a sleeving mode, the hybrid stent is of a net-shaped structure formed by composite weaving of degradable metal wires and non-degradable metal wires, the temporary supporting function of degradable materials is utilized, and the function of the hybrid stent is achieved. And a durable flexible framework is constructed by relying on non-degradable wires. The internal arteriovenous fistula stent can provide necessary constraint for blood vessels, especially anastomotic stoma areas in the early stage of a surgery so as to inhibit excessive expansion and intimal hyperplasia caused by abnormal stress, the degradable metal wires are gradually degraded along with gradual completion of vein artery remodeling, the stent can still maintain a complete net-shaped structure, and the stent has the advantages of being simple in structure and convenient to use. Meanwhile, the restraining effect can be gradually reduced, rigid restraining is avoided, and therefore the possibility that the stent structure loses efficacy and the blood vessel is restenosis is greatly reduced while the smoothness of the blood vessel is protected.

The invention provides a blood vessel expandable device and a preparation method, the blood vessel expandable device comprises a tubular stent body and a coating on the surface of the stent body, and the stent body has an expanded state and a compressed state; the coating at least comprises a middle layer on the surface of the stent body and a heparin membrane layer on the surface of the middle layer. According to the coating of the blood vessel expandable device, the middle layer serves as a link for connecting the heparin membrane layer and the blood vessel expandable device, the heparin membrane layer and the middle layer as well as the middle layer and the stent body can be in covalent bond and / or electrostatic adsorption connection, heparin can be completely or partially reserved on the device, and the coating is not prone to falling off; heparin in the coating, especially heparin with a certain content and low molecular weight, can control complications after implantation in stages after implantation, for example, the problem that thrombus easily occurs in the early stage can be better solved through the slow-release coating in the early stage, thrombus, intimal hyperplasia, stenosis and the like can be effectively controlled in the later stage, and endothelialization is promoted.

The invention relates to the technical field of biomedicine, in particular to application of a gene inhibitor in preparation of a medicine for preventing or treating restenosis after vascular injury. Specific knockdown or knockout of TRIM65 or MYH9 can inhibit formation of neointima, excessive intima neogenesis is the core pathological feature of restenosis after vascular injury, and therefore the TRIM65 inhibitor or MYH9 inhibitor can be used for preparing the medicine for preventing or treating restenosis after vascular injury.

In one aspect, the disclosure relates to unimolecular micelles having N-hydroxysuccinimide ester (NHS), sulfo-NHS terminal groups, or other adhesive terminal groups, compositions including the same, methods of making the same, and methods of treating intimal hyperplasia in a subject using the same. In some aspects, the unimolecular micelles can further include fluorescent labels or drugs for treating intimal hyperplasia. In one aspect, the unimolecular micelles and compositions comprising the same are biocompatible, non-toxic, and non-inflammatory. In another aspect, the unimolecular micelles and compositions are substantially free from hydrogel, or are completely free from hydrogel. In still another aspect, the disclosed compositions and methods can be easily and quickly deployed in the operating room. Also disclosed is a method of applying the unimolecular micelles and compositions via direct penbrush painting.

The invention belongs to the technical field of minimally invasive interventional medical instruments, and discloses a medicine-carrying balloon catheter for treating pulmonary artery stenosis caused by takayasteritis, which comprises a handle, one end of the handle is fixedly connected with one end of a near-end rod, the other end of the near-end rod is fixedly connected with one end of a far-end rod, the other end of the far-end rod is fixedly connected with a balloon, and the balloon is fixedly connected with a catheter. The balloon is divided into a circular truncated cone shape and a cylindrical shape; the drug coating is arranged on the outer surface of the balloon, and the drug coating is used for carrying treatment drugs; the triangular wires are arranged on the outer side wall of the balloon in the length direction of the balloon. Through balloon dilatation and the micro-cutting effect of the triangular wire, the pulmonary artery stenosis part is effectively dilated, meanwhile, anti-inflammatory and anti-proliferation drugs are released in a targeted mode, inflammatory response and vascular intimal hyperplasia are inhibited, the restenosis occurrence rate is reduced, and the balloon dilatation triangular wire has the advantages of being high in safety and adaptability, remarkable in treatment effect and the like.

The invention belongs to the technical field of transplanted vascular remodeling diagnosis and treatment, and discloses application of a reagent for inhibiting or detecting Fasn and a medicine for preventing and / or treating transplanted vascular remodeling. Experimental research discovers that a group of novel macrophages capable of self-synthesizing lipid exist in the transplantation blood vessel reconstruction process, and Fasn is remarkably activated, so that intracellular lipid accumulation is caused, and the macrophages are promoted to be converted into foam cells. In-vitro studies show that by inhibiting the activity of the Fasn enzyme or down-regulating the expression of the Fasn enzyme, the transformation of macrophages to foam cells can be obviously inhibited, and the synthesis of lipid in cells can be reduced. Based on the discovery, the nucleic acid medicine constructed by adopting the siRNA is used for treating and / or relieving transplanted vascular remodeling. In-vivo experiments further prove that the nucleic acid medicine can remarkably inhibit intimal hyperplasia of transplanted blood vessels and reduce the neointimal / medial membrane ratio, so that the therapeutic effect is achieved. The method has a good application prospect.

The application provides a directional thrombolytic pro-endothelialization composite small-caliber artificial blood vessel and a preparation method thereof. The method activates and chemically modifies the surface of an expanded polytetrafluoroethylene (ePTFE) artificial blood vessel through plasma treatment, introduces active carboxyl groups and covalently grafts a pro-endothelial adhesion polypeptide REDV; then, by using the strong adhesion of a polydopamine (PDA) coating, nano-hydrogel particles loaded with thrombolytic drugs t-PANPs are fixed on the inner surface of the blood vessel. The application actively recruits endothelial cells by the bottom layer of the REDV polypeptide, and at the same time, realizes on-demand and controlled release of t-PA for thrombolysis by the upper layer of the nano-hydrogel, thereby solving the problems of easy thrombosis and intimal hyperplasia of the small-caliber artificial blood vessel. The preparation process condition is mild, the performance is stable, the synergistic effect of antithrombosis and pro-endothelialization is realized, and the application has a good clinical application prospect.

The invention discloses a function-integrated blood flow guiding device simulating endothelium-derived exosome and a preparation method. The device comprises a blood flow guiding device and a functional coating integrated on the blood flow guiding device, the functional coating comprises a base layer capable of catalytically releasing endogenous nitric oxide and an outer layer loaded on the surface of the base layer, and the outer layer and the base layer can jointly form an exosome-like biological function integration surface. On one hand, the natural anti-acute blood coagulation function can be played, and on the other hand, through the anti-inflammatory effect, the function of improving the endothelial cell activity and the function of continuously releasing endogenous nitric oxide gas signal molecules, the surface endothelialization process of the device is synergistically promoted, and the local anti-inflammatory microenvironment is maintained; therefore, the device is endowed with an excellent long-term antithrombotic function and can inhibit vascular intimal hyperplasia, so that the device can adapt to higher and more complex blood vessel microenvironments and clinical treatment requirements, and finally the treatment target of efficiently guaranteeing long-term smoothness of tumor-carrying blood vessels is achieved.

The invention relates to the technical field of medical supplies. An anti-displacement dialysis puncture needle with a dynamic anchoring structure comprises a puncture needle, the puncture needle comprises a needle body, a puncture needle main body and a tube body, and a plurality of expandable anchoring claws are arranged on the surface of the needle body; a silica gel wing is rotationally arranged on the puncture needle main body; a locking mechanism is arranged in the puncture needle main body; and the anchoring claw is made of a phase-change material. According to the anti-displacement dialysis puncture needle with the dynamic anchoring structure, the stability of the puncture needle can be guaranteed through in-vitro dynamic supporting and in-vivo thermal response anchoring, the in-vivo displacement rate of the puncture needle is effectively reduced, friction between the needle tip and the inner wall of a blood vessel cavity is effectively avoided, and the safety of a patient is guaranteed; the technical problems that in the prior art, an existing traditional straight puncture needle is high in displacement rate in the dialysis process, a needle tip freely shakes in a blood vessel cavity, intimal hyperplasia is caused by repeated friction, and higher practical requirements cannot be met are solved.

The invention discloses a small molecular short peptide for resisting vascular remodeling caused by Zika virus and application of the small molecular short peptide. The small molecule short peptide is constructed by fusing a cell-penetrating peptide and a functional amino acid sequence, and the amino acid sequence is shown as SEQ ID NO.1. The oligopeptide can be used for preparing drugs for preventing or treating vascular diseases induced by virus infection, especially for aorta vascular intimal hyperplasia and phenotype conversion of vascular smooth muscle cells from a contraction type to a synthetic type. The oligopeptide can reduce the crotonylation modification level of MYH9 protein in vascular smooth muscle cells and promote expression of alpha-smooth muscle actin and smooth muscle 22 alpha protein in vascular tissues, so that vascular pathological damage caused by virus infection is improved, the blood vessel thickness is reduced, and the ratio of a medial membrane to an intimal membrane is increased. The invention also provides a pharmaceutical composition containing the small molecule oligopeptide. The invention provides a new treatment strategy for prevention and treatment of virus infection related vascular diseases.

This application discloses a method for detecting endometrial hyperplasia, comprising: acquiring a target image obtained by endoscopic imaging and the patient's case information corresponding to the target image; the case information includes height, weight, age, and / or history of diabetes; inputting the case information and the preprocessed target image into a hyperplasia recognition model for processing; obtaining the hyperplasia category corresponding to the target image through a first classification method of the hyperplasia recognition model; and / or obtaining binary classification information on whether the target image corresponds to endometrial cancer and the probability information of corresponding endometrial cancer through a second classification method of the hyperplasia recognition model. Applying this application can improve the classification accuracy of endometrial hyperplasia.